TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: HBV Prevention for Homeless at Risk for HBV/HCV/HIV
Brief Summary: In this study, researchers from UCLA and Friends Community Center will work together in designing a program to assist young homeless stimulant-using gay and bisexual homeless men to complete the hepatitis vaccine and in reducing drug and sexual activity. Using nurse case management strategies, found successful with homeless adults as well as contingency management strategies, found successful with gay and bisexual homeless adults by the community partners, the investigators will evaluate the effectiveness of a program that combines both strategies. As stimulant use threatens to increase homeless persons' risk of exposure to hepatitis A and B viruses, particularly among young users who may not yet be HBV-infected, this research is targeted to engage this group in treatment, until they are suitably protected from HBV, and hopefully reduce risk for HCV and HIV as well.


Options:
A: Inclusion Criteria:

1. homeless males self-reporting gay or bisexual behaviors in the last 12 months
2. age 18-39
3. methamphetamine and/or cocaine/crack use currently or in the last three months
4. no self-reported participation in drug treatment in the last 30 days
5. willing to provide informed consent
6. willing to undergo hepatitis B and C and HIV antibody testing at baseline
7. found to be HBV antibody negative

Exclusion Criteria:

1. persons with Guillian Barre, or allergy to yeast or neomycin
2. monolingual speakers of languages other than English or Spanish
3. persons judged to be cognitively impaired by the nurse
B: Inclusion Criteria:

* patient is 18 years or older
* Alcohol and/or Drug screening score that indicates at least mild problem severity.

Exclusion Criteria:

* medical or psychiatric complications
* substance use is mild enough that further intervention is not warranted
* patient reports plans to leave the area within the next 12 months
* patient is unable to provide valid informed consent
C: Inclusion Criteria:

* HCV antibody positive
* age between 18 and 35 years old;
* reported injection drug use in the past 6 months
* willing to provide a blood sample for liver function testing

Exclusion Criteria:

* HIV antibody positive
* planned on moving from city within the next 12 months;
* unable to comprehend English well enough to complete English-only assessments and group sessions
D: Inclusion Criteria:

* New residents of Skid Row Housing Trust receiving permanent supportive housing

Exclusion Criteria:

* Age younger than 18
* Does not speak English
* Cognitively impaired either by identifying those having a diagnosis of dementia in the new resident intake interview or using the Short Blessed Scale Exam)
* Does not screen positive for past -year harmful AOD use using the AUDIT-C (a score \> 4 for men and \> 3 for women) and DAST (a score greater than 2).

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Stepped Care to Optimize Pain Care Effectiveness (SCOPE)
Brief Summary: Pain is the most common physical symptom in primary care, accounting for an enormous burden in terms of patient suffering, quality of life, work and social disability, and health care and societal costs. Pain is particularly prevalent among veterans. Four major barriers to optimal care include underdetection of pain, inadequate initial treatment, failure to monitor adherence and symptom response, and failure to adjust treatment in patients not responding or intolerant of initial therapy. Therefore, we propose to conduct the Stepped Care to Optimize Pain care Effectiveness (SCOPE) study, a randomized clinical effectiveness trial in primary care.


Options:
A: Inclusion Criteria:

* Patients currently receiving primary care at Portland VAMC
* Diagnosed musculoskeletal chronic pain condition lasting at least 3 months
* Currently experiencing moderate to severe symptoms as per screening
* Willingness to complete 6 and 12 month interviews
* Regular access to a telephone

Exclusion Criteria:

* Dementia or cognitive disturbance
* Diagnoses of fibromyalgia, chronic fatigue or somatization disorder Terminal illness
* Designated guardian
* Drug-seeking behavior flag in medical record
B: Inclusion Criteria:

* Meets criteria for major depression based on a score of greater than 2 for five or more symptoms, including one of the two cardinal depression symptoms and a nine-item depression scale of the Patient Health Questionnaire (PHQ-9) score of greater than 10
* Patient with diabetes
* Has attended two community safety net clinics

Exclusion Criteria:

* Current suicidal ideation
* Score of 8 or greater on the Alcohol Use Disorders Identification Test (AUDIT)
* Recent use of lithium or antipsychotic medication
C: Inclusion Criteria:

SCOPE will enroll 250 primary care veterans with persistent (3 months or longer) musculoskeletal pain of moderate severity and randomize them to either the stepped care intervention or usual care control group.

Exclusion Criteria:

Individuals who:

* have filed a pain-related disability claim in the last 6 months;
* do not speak English;
* have moderately severe cognitive impairment;
* have schizophrenia, bipolar disorder, or other psychosis;
* are actively suicidal;
* have current illicit drug use; or
* have an anticipated life expectancy of less than 12 months.
D: Inclusion Criteria:

* Enrolled as a pt in the VA Healthcare System
* screens positive for major depression
* has a scheduled visit at a primary care site taking part in the study

Exclusion Criteria:

* severe alcohol abuse
* psychosis
* dementia
* acutely suicidal (at screening)
* lack of access to or ability to use a phone

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: l Prospective Clinical Investigation on the Acoustic Stimulation With the "Coordinated Reset of Neural Subpopulations" in the Treatment of Chronic Tinnitus
Brief Summary: There are many treatments for chronic tinnitus that have been claimed, with varying degrees of statistical reliability. None of those treatments can eradicate the tinnitus completely. Some therapies can reduce the tinnitus symptoms (loudness, annoyance) up to 30%. Thus there is still a need of new treatments that can reduce considerably the tinnitus symptoms and improve the QOL of subjects.

Trial objectives:

* The aim of this trial is the improvement of the QOL (quality of live) by reducing the Tinnitus- Symptoms of the patient.
* To confirm the efficacy and safety of the coordinated reset technology.

These objectives will be assessed:

* By subjective and objective measurements of the Tinnitus symptoms, loudness and annoyance.


Options:
A: Inclusion Criteria:

* Subjective tinnitus complaints
* Referred to Tinnitus centre Limburg

Exclusion Criteria:

* Not being able to write and read in Dutch
B: Inclusion Criteria:

* mild to moderate sensorineural hearing loss
* tinnitus (THI \> 20)
* first user

Exclusion Criteria:

* profound hearing loss
* conductive hearing loss
* THI \< 20
C: Inclusion Criteria:

(i) Chronic subjective tinnitus (experienced for over 6 months)

(ii) Aged 18 + years old

(iii) Not currently receiving treatment for tinnitus from the National Health Service or other sources

Exclusion Criteria:

(i) Significant distress (Beck anxiety score \>25, Beck depression score \>13)

(ii) Hyperacusis (Khalfa Hyperacusis Questionnaire score \>27)

(iii) Significant bilateral hearing loss (\>39 decibel at all tested frequencies)
D: Inclusion Criteria:

* Mentally healthy people
* Chronic tonal Tinnitus
* Older than 18 years
* Signature of the patient informed consent
* No participation in other tinnitus therapy during the clinical investigation

Exclusion Criteria:

* A necessity for hearing aid
* Auditory hallucination
* Symptomatic hearing disorders
* "Morbus Meniere",
* Tinnitus due to temporomandibular joint disorders
* Subjects who can't perceive therapeutic tones
* Brainstem diseases
* Psychiatric disorders
* Objective Tinnitus
* Insufficient treatment of general disorders, anemia, tumor, dialysis, hypertonus ect.

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A+ Head Start Intervention for Smoke Free Homes
Brief Summary: Environmental tobacco smoke (ETS0, also known as secondhand smoke, is the combination of smoke given off by the burning end of a tobacco product and the smoke exhaled by the smoker. Children exposed to ETS are at an increased risk of sudden infant death syndrome (SIDS), ear infections, colds, pneumonia, bronchitis and more severe asthma. ETS can also slow the growth of children's lungs and can cause them to cough, wheeze and fell breathless. The purpose of this study is to determine the effectiveness of a motivational interviewing-based program in reducing ETS exposure and improving lung health among children who are enrolled in a Head Start program and whose households include a smoker.


Options:
A: Inclusion Criteria:

* Inclusion Criteria-Patients:
* Diagnosis of lung cancer
* Ages 18 or older
* Able to consent

Inclusion Criteria-Family Members:

* Patient has given consent to contact the family member
* Ages 18 or older
* Speaks and reads English
* Cognitively able to give consent to participate
* Has access to a telephone
* Smoked at least 100 cigarettes in his/her life
* Smoked any cigarettes in the prior 7 days at screening

Exclusion Criteria:

* Patients or family members who do not meet inclusion criteria
B: Inclusion Criteria:

* age ≥ 18 years
* smoked tobacco during the prior 30 days
* have an active phone number
* provide consent in English, Spanish or Mandarin

Exclusion Criteria:

* Patients will be excluded if they use only smokeless tobacco or products such as betel (since there is not yet efficacy data for treating use of these tobacco products in the inpatient setting)
* are pregnant or breastfeeding
* are discharged to an institution (e.g. jail/prison, nursing home, long-term psychiatric facility).
C: Inclusion Criteria:

* currently homeless
* smoke 5 or more cigarettes per day
* smoked 100 cigarettes in lifetime
* aged 18 years or older

Exclusion Criteria:

* unstable mental illness
* pregnancy
* current history of psychoactive or alcohol dependence or psychotic disorder
* cognitive impairment
D: Inclusion Criteria:

* Child enrolled in Baltimore City Head Start
* Smoker living in the home with child

Exclusion Criteria:

* No smoker in home with child
* Does not speak English
* Is enrolled in other respiratory research study

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A+ Head Start Intervention for Smoke Free Homes
Brief Summary: Environmental tobacco smoke (ETS0, also known as secondhand smoke, is the combination of smoke given off by the burning end of a tobacco product and the smoke exhaled by the smoker. Children exposed to ETS are at an increased risk of sudden infant death syndrome (SIDS), ear infections, colds, pneumonia, bronchitis and more severe asthma. ETS can also slow the growth of children's lungs and can cause them to cough, wheeze and fell breathless. The purpose of this study is to determine the effectiveness of a motivational interviewing-based program in reducing ETS exposure and improving lung health among children who are enrolled in a Head Start program and whose households include a smoker.


Options:
A: Inclusion Criteria:

* Physician-diagnosed asthma
* Mild persistent to severe persistent asthma
* Ages 3-10 years
* Attending school in the Rochester City School District preschools or elementary schools
* Signed physician permission to enroll the child
* Parent or caregiver must consent to the intervention

Exclusion Criteria:

* Inability to speak and understand either English or Spanish
* No access to a working phone for follow-up surveys
* The family planning to leave the school district within fewer than 6 months
* The child having other significant medical conditions that could interfere with the assessment of asthma-related outcome measures
* children in foster care or other situations in which consent cannot be obtained from a guardian
* Current participation in other local asthma interventions
B: Inclusion Criteria:

* Child enrolled in Baltimore City Head Start
* Smoker living in the home with child

Exclusion Criteria:

* No smoker in home with child
* Does not speak English
* Is enrolled in other respiratory research study
C: Inclusion Criteria:

* at least 18 years of age
* English-speaking
* parent or legal guardian of child under 11 years old who lives with him/her
* daily smoker

Exclusion Criteria:

* non-nicotine drug dependence
* psychiatric disturbance (bipolar, schizophrenia, psychosis)
* pregnant
* inadequate health literacy
D: Inclusion Criteria:

* Smoking parents with babies minor 1 year-old

Exclusion Criteria:

* Parents reporting diagnosis of major psychiatric illnesses
* Parents reporting active addictive substances consumption
* Parents in active smoking cessation treatment

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Haemorrhagia Postpartum: an Implementation Study on the NVOG Guidelines and MOET Instructions
Brief Summary: The objectives of this study is first to asses to what extent the guidelines of the Dutch Society of Obstetrics and Gynaecology (NVOG) and the MOET (Management of Obstetric and Emergencies and Trauma) instructions for haemorrhagia postpartum have been implemented in current care in the Dutch practice. Second to study barriers and facilitators for guideline adherence and to develop and test a tailored implementation strategy, based on these findings.


Options:
A: Inclusion Criteria:

* primary atonic postpartum hemorrhage after vaginal delivery

Exclusion Criteria:

* Patients who delivered by caesarean section
* Retained placenta
* Traumatic postpartum hemorrhage
* Associated coagulopathy
* Chronic medical illness (hepatic , renal diseases)
* Refusal to participate in the study.
B: Inclusion Criteria:

* woman with a high risk for haemorrhagia post partum

Exclusion Criteria:

* woman who refuses to participate
C: Inclusion Criteria:

* pregnant with a fetus \>/=24 weeks gestational age
* non-emergent cesarean delivery
* postpartum hemorrhage deemed the result of uterine atony

Exclusion Criteria:

* non-English speaking patients requiring an interpreter
* any hypertensive disorder
* cardiovascular disease
* asthma
* refusal of transfused blood products
* coagulopathy or abnormal coagulation lab values
* hypersensitivity to methylergonovine maleate or 15-methyl prostaglandin
D: Inclusion Criteria:

* For Providers: Health providers who attend births in participating health facility and consent to be assessed at the time of enrollment and at several points in time over two years.
* For Clinical mentors: being an experienced skilled birth attendant and likely to remain at the facility during the study period

For Women in Labor and Delivery and Newborns: Women in any stage of labor in participating facility who consent to observation of their delivery and care of their newborn (or consent from the next of kin if the woman is incapacitated and not able to provide consent)

Facility In-charges and Stakeholders: Facility in-charges at sampled health facilities; stakeholders identified by Jhpiego senior managers as being influential in maternal and newborn health policy decisions in Uganda.

Exclusion Criteria:

* Providers: has \<1 year of experience, and has plans to be transferred to another facility or leave the facility soon
* Other types of participants: none

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Clinical and Cost-effectiveness of Mindfulness Based Cognitive Therapy, Maintenance Antidepressant Medication and Its Combination in the Prevention of Relapse in Patients With Recurrent Depression
Brief Summary: The purpose of this study is to investigate the (cost)effectiveness of mindfulness based cognitive therapy (MBCT) compared to that of antidepressant medication, and its combination with regard to the prevention of relapse or recurrence in patients with recurrent depression.


Options:
A: Inclusion Criteria:

* Recurrent Major Depressive Episode (at least 3 previous episodes)
* Treatment with therapeutic dose of antidepressant medication during past six months
* Currently in full or partial remission

Exclusion Criteria:

* Bipolar disorder (current and previous (hypo)manic episodes)
* Psychotic disorder (current and previous)
* Neurological or somatic illness affecting depression or outcome measures
* Current alcohol or drugs dependency
* Use of high dosage benzodiazepines (\> 2 mg Lorazepam equivalents daily)
* Recent Electro Convulsive Therapy (\< 3 months ago)
B: Inclusion Criteria:

* Vascular- or Alzheimer Dementia
* Nursing Homes resident for 3 months or more
* Given antipsychotics or antidepressants for 3 months or more
* Clinical Dementia rating 1, 2 or 3

Exclusion Criteria:

* Dementia of other origin
* Psychiatric disease
* Life expectancy less than 3 months
* Acute infection last 10 days
* Unstable Diabetes Mellitus
* Terminal disease
C: Inclusion Criteria:

• Having received prescriptions for antidepressants in primary care for at least the past nine months

Exclusion Criteria:

* Current treatment by a psychiatrist
* Current diagnosis of substance use disorder
* Non-psychiatric indication for long-term antidepressant usage (i.e. neuropathic pain)
* Having participated in a mindfulness training (\> 3 sessions) within the last 5 years
* Inability to perform the assessments due to cognitive or language difficulties
* Younger than 18 years
D: Inclusion Criteria:

* Principal (i.e., most severe or pressing problem) or co-principal current diagnosis of generalized anxiety disorder
* Pretreatment score of at least 17 on Hamilton Anxiety Rating Scale

Exclusion Criteria:

* Principal diagnosis other than GAD
* Clinically judged too psychiatrically unstable to participate in the study
* Cognitive impairment or dementia
* Alcohol or other substance use disorder within 6 months prior to study entry
* Lifetime diagnosis of schizophrenia, schizoaffective disorder, delusional disorder, or bipolar disorder
* Serious, unstable, or terminal medical condition that would compromise study participation or preclude the use of escitalopram, as determined by a review of medical records
* Use of psychotropics that could not be safely tapered and discontinued for at least 2 weeks prior to study entry
* Use of depot neuroleptics within 6 weeks prior to study entry
* Unwillingness to terminate other forms of psychotherapy
* Already received adequate trial of escitalopram or CBT

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized, Head-to-Head, Single-Blind Study to Compare the Efficacy and Safety of Subcutaneous Abatacept Versus Subcutaneous Adalimumab, Both With Background Methotrexate, in Biologic-Naive Subjects With Rheumatoid Arthritis
Brief Summary: The purpose of this study is demonstrate that subcutaneous abatacept is non-inferior (no worse than) to subcutaneous adalimumab in the treatment of subjects with rheumatoid arthritis who are biologic naive


Options:
A: Inclusion Criteria:

* adult patients at least 18 years of age with active RA for at least 3 months;
* patients of reproductive potential must be using reliable methods of contraception.

Exclusion Criteria:

* major surgery (including joint surgery) within 8 weeks before entering study or planned major surgery within 6 months after entering study;
* treatment with methotrexate (MTX) within 6 months of entering study;
* patients who have stopped previous MTX treatment due to toxicity or lack of response;
* women who are pregnant or breast-feeding.
B: Inclusion Criteria:

* Moderate to severe Rheumatoid arthritis (RA) according to American College of Rheumatology (ACR) criteria
* Methotrexate failure
* Naive to RA biologics
* ≤5 years duration of disease
* Disease Activity Score-28 C-reactive protein (DAS28 CRP) ≥ 3.2
* Willingness to self-inject subcutaneous (SC) drug

Exclusion Criteria:

* Previous or current medical conditions that are warnings against the use of tumor necrosis factor (TNF)-blocking agents
* History of active or chronic hepatitis
* Cancer in the last 5 years
* History of severe chronic or recurrent bacterial or viral infections
* Risk of tuberculosis
* Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, Gastro-intestinal, pulmonary, cardiac, neurologic, or cerebral disease
C: Inclusion Criteria:

* Have a diagnosis of RA for less than or equal to 3 years
* Be 18 years of age or older at the time of diagnosis

Exclusion Criteria:

* Pregnant or lactating women
* History of chronic infection, such as hepatitis, pneumonia, or chronic skin infections
* Active TB or evidence of latent TB
D: Inclusion Criteria:

* Subjects who have participated in a randomized "qualifying" study of CP-690,550 for the treatment of rheumatoid arthritis

Vaccine sub-study visit

* Subjects actively participating in Study A3921024 must have completed at least 3 months of continuous 10 mg BID CP-690,550 treatment in A3921024 as defined by \>80% compliance with prescribed dose consumption of CP-690,550 over the previous 3 months.

Exclusion Criteria:

* Serious medical conditions that would make treatment with CP-690,550 potentially unsafe

Vaccine sub-study visit

1. Any documented influenza or pneumococcal infection within the last 3 months prior to randomization in this study
2. Received any vaccine within 1 month prior to randomization in this study
3. Received an influenza vaccine within 6 months or a pneumococcal vaccine within 5 years of randomization in this study.

Answer: B